Coherus BioSciences Inc (CHRS)
0.7284
+0.06
(+8.72%)
USD |
NASDAQ |
Nov 05, 16:00
0.732
0.00 (0.00%)
After-Hours: 16:28
Coherus BioSciences Enterprise Value: 182.05M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 182.05M |
| November 01, 2024 | 188.15M |
| October 31, 2024 | 190.69M |
| October 30, 2024 | 191.25M |
| October 29, 2024 | 190.50M |
| October 28, 2024 | 187.98M |
| October 25, 2024 | 195.18M |
| October 24, 2024 | 196.34M |
| October 23, 2024 | 198.18M |
| October 22, 2024 | 204.10M |
| October 21, 2024 | 205.76M |
| October 18, 2024 | 206.57M |
| October 17, 2024 | 202.58M |
| October 16, 2024 | 207.00M |
| October 15, 2024 | 209.71M |
| October 14, 2024 | 213.05M |
| October 11, 2024 | 218.94M |
| October 10, 2024 | 216.68M |
| October 09, 2024 | 220.06M |
| October 08, 2024 | 224.67M |
| October 07, 2024 | 228.13M |
| October 04, 2024 | 224.67M |
| October 03, 2024 | 224.67M |
| October 02, 2024 | 222.37M |
| October 01, 2024 | 222.37M |
| Date | Value |
|---|---|
| September 30, 2024 | 224.67M |
| September 27, 2024 | 225.82M |
| September 26, 2024 | 226.98M |
| September 25, 2024 | 219.02M |
| September 24, 2024 | 220.06M |
| September 23, 2024 | 224.67M |
| September 20, 2024 | 222.37M |
| September 19, 2024 | 235.04M |
| September 18, 2024 | 225.82M |
| September 17, 2024 | 224.67M |
| September 16, 2024 | 225.82M |
| September 13, 2024 | 254.63M |
| September 12, 2024 | 253.48M |
| September 11, 2024 | 258.08M |
| September 10, 2024 | 261.54M |
| September 09, 2024 | 255.78M |
| September 06, 2024 | 247.71M |
| September 05, 2024 | 256.93M |
| September 04, 2024 | 255.78M |
| September 03, 2024 | 261.54M |
| August 30, 2024 | 265.00M |
| August 29, 2024 | 268.45M |
| August 28, 2024 | 261.54M |
| August 27, 2024 | 265.00M |
| August 26, 2024 | 271.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
182.05M
Minimum
Nov 04 2024
1.592B
Maximum
Feb 21 2020
913.70M
Average
951.06M
Median
Jul 23 2021
Enterprise Value Benchmarks
| Repligen Corp | 7.600B |
| Evoke Pharma Inc | 0.0252M |
| Personalis Inc | 180.68M |
| Maravai LifeSciences Holdings Inc | 1.389B |
| Tempus AI Inc | 7.591B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.92M |
| Revenue (Quarterly) | 64.98M |
| Total Expenses (Quarterly) | 85.49M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 56.34% |
| Profit Margin (Quarterly) | -19.88% |
| Earnings Yield | -54.91% |
| Normalized Earnings Yield | -236.65 |